lutetium has been researched along with Melanoma in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Begin-Colin, S; Bordeianu, C; Boutry, S; Chezal, JM; Cinotti, E; Felder-Flesch, D; Jouberton, E; Labeille, B; Laurent, S; Meyer, F; Miot-Noirault, E; Muller, RN; Parat, A; Perrot, JL; Piant, S; Walter, A; Zbaraszczuk-Affolter, C | 1 |
Chakraborty, S; Pillai, MR; Sarma, HD; Vimalnath, KV | 1 |
Anderson, CJ; Beaino, W; Nedrow, JR | 1 |
Alonso, O; Cabral, P; Calzada, V; Camacho, X; Chammas, R; Fernandez, M; Gambini, JP; Riva, E | 1 |
Fisher, DR; Miao, Y; Quinn, TP | 1 |
Bakker, WH; de Herder, WW; Feelders, RA; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; van Essen, M; Wolbers, JG | 1 |
Miao, Y; Quinn, TP; Shelton, T | 1 |
7 other study(ies) available for lutetium and Melanoma
Article | Year |
---|---|
Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles.
Topics: Animals; Biopsy; Cell Line, Tumor; Humans; Injections, Intravenous; Lutetium; Magnetic Resonance Imaging; Male; Melanins; Melanoma; Mice; Microscopy, Confocal; Nanoparticles; Polymers; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Skin; Skin Neoplasms; Tissue Distribution | 2018 |
Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Topics: Animals; Dimerization; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma; Mice; Octanols; Peptides, Cyclic; Radiation Dosage; Radioactive Tracers; Radiochemistry; Radioisotopes; Water | 2013 |
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Topics: Animals; Cell Line, Tumor; Gallium Radioisotopes; Humans; Integrin alpha4beta1; Lutetium; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Skin Neoplasms | 2015 |
177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.
Topics: Animals; Bevacizumab; Lutetium; Male; Melanoma; Mice; Mice, Inbred C57BL; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Succinimides; Tissue Distribution | 2017 |
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
Topics: alpha-MSH; Animals; Kidney; Lutetium; Melanoma; Mice; Mice, Inbred C57BL; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes | 2006 |
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals | 2006 |
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
Topics: alpha-MSH; Animals; Arginine; Chelating Agents; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Melanoma; Mice; Radiography; Radioisotopes; Survival Analysis | 2007 |